Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
about
Crystal Structures of TbCatB and Rhodesain, Potential Chemotherapeutic Targets and Major Cysteine Proteases of Trypanosoma bruceiThree drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in UgandaNECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sicknessMining a cathepsin inhibitor library for new antiparasitic drug leadsSafety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sicknessHighly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferaseContribution of dithiol ligands to in vitro and in vivo trypanocidal activities of dithiaarsanes and investigation of ligand exchange in an aqueous solutionHuman African trypanosomiasis in South Sudan: how can we prevent a new epidemic?Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.The World Health Organization and the Pharmaceutical Industry. Common areas of interest and differing views.Treatment perspectives for human African trypanosomiasis.Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda.A plethora of targets, a paucity of drugs: progress towards the development of novel chemotherapies for human African trypanosomiasis.Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections.Predicting the protein targets for athletic performance-enhancing substances.Human African trypanosomiasis in endemic populations and travellers.Key indicators for the monitoring and evaluation of control programmes of human African trypanosomiasis due to Trypanosoma brucei gambiense.Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.Lipophilic conformationally constrained spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acid analogues as trypanocidal and leishmanicidal agents: an extended SAR study.Winterbottom's sign and hypertrophic cardiomyopathy.2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid acute administration diferentially change biochemical parameters in mice.African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.Neuropathology of naturally occurring Trypanosoma evansi infection of horses.Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
P2860
Q27662211-6A51FE07-5D6A-4885-B990-B8BC22622B6BQ28469079-227166AE-D76D-488D-8DE3-39276CB6D80FQ28474074-780DCD2E-E659-4F04-B098-199AF7DE5129Q28478016-FDDF5A77-7F00-4161-BE4C-3CEE4B1AC987Q28483501-A7F895B9-A5BD-4304-981C-FD19A320BFA9Q28535374-F33FA809-602C-4C84-AA9E-BD799AE14702Q33593765-1478DAB6-17ED-4DCF-96FB-89FD5C44F458Q34293008-1982D634-3392-4E9D-AD61-A7F69C447F77Q34589130-A3165EA2-F679-4C38-9DE3-10DED9EAD9C5Q34761290-D75463AB-5437-4DFD-9FD6-5D5E6FBADF96Q35095248-5459CA66-1732-42E5-9018-4BDF7599C100Q35126176-046444A3-493C-4081-83DB-FDB2BB44C8D2Q35917161-0A3516FE-717F-46AD-AF66-0C23D265D5D1Q36009318-1910951C-FFED-4537-B809-BC1A38C9AF7DQ36189949-7065F51E-333E-49FE-B62F-738B749A0FA3Q36982836-9F77523F-90EF-496B-849F-D60949177324Q37929054-B4E30609-F12B-4D4E-9B27-BC2AB3F8BAB4Q38887279-E9E55D62-668B-4D2A-A228-E5F4CDBA2863Q38912273-07767A16-7247-4159-B7DA-5CD663CB6E9CQ39223286-1FD789BF-BC9D-46D1-A617-A0E31FABBF90Q39633271-B12636F6-ED01-4F63-A072-BC67FAACF0D4Q44114329-5A39B241-366E-4D37-B1A8-D5E2E9FE24D6Q45310231-2723A3BE-0B1C-4F17-B7C3-82C311238C12Q46057445-40998FAA-F802-4591-BA27-7B600EC1AD9AQ48716797-9EF37182-CC11-4B5E-B213-DAAF68F4CF1EQ49596380-71275C1D-917D-4C4F-9BB1-711B983E1E4EQ55322154-518C611C-D103-4D76-9164-ED4C81F0A82E
P2860
Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@en
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@nl
type
label
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@en
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@nl
prefLabel
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@en
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@nl
P2093
P2860
P921
P1476
Risk factors for encephalopath ...... i gambiense sleeping sickness.
@en
P2093
P2860
P356
10.1016/0035-9203(95)90673-8
P577
1995-01-01T00:00:00Z